MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3892/mco.2019.1923

Медицинская библиотека · Molecular and clinical oncology · 2019

Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature.

Izumi Hiroki, Kodani Masahiro, Kurai Jun, Takeda Kenichi, Okazaki Ryota, Yamane Kohei, Teruya Yasuhiko, Yamamoto Akihiro, Sueda Yuriko, Yanai Masaaki, Tanaka Natsumi, Sakamoto Tomohiro, Yamaguchi Kosuke, Makino Haruhiko, Igishi Tadashi, Yamasaki Akira

СтатьяПеревод пока не подготовлен

Аннотация

Immune checkpoint inhibitors (ICIs), including nivolumab, have exhibited substantial benefits in the treatment of several types of cancers. However, treatment with ICIs is often accompanied by immune-related adverse events (irAEs), and a clear understanding of the precise indications and management of irAEs is important for harnessing the full potential of these agents. While skin- or gastrointestinal-associated irAEs have been relatively well studied, there are few reports regarding nivolumab-induced cholangitis. We retrospectively reviewed data from patients with advanced or recurrent non-small cell lung cancer who were treated with nivolumab between December 2015 and December 2018 at Tottori University in Japan. Among the 59 patients, we identified four patients who experienced nivolumab-induced cholangitis. Of these four patients, stable disease (SD) was observed in two patients (50%), while partial response (PR) was achieved in two patients (50%) under nivolumab treatment. Patients were treated with corticosteroid alone (n=2) or in combination with mycophenolate mofetil (MMF) (n=2); these treatments resulted in improvements in nivolumab-induced cholangitis in three patients. In conclusion, the present retrospective study identified four cases of nivolumab-induced cholangitis. The combination of corticosteroid and MMF was effective in two cases with grade 4 nivolumab-induced cholangitis. Further reports are needed to establish the optimal management of patients with this irAE.

Для цитирования: Izumi Hiroki, Kodani Masahiro, Kurai Jun, Takeda Kenichi, Okazaki Ryota, Yamane Kohei, Teruya Yasuhiko, Yamamoto Akihiro, Sueda Yuriko, Yanai Masaaki, Tanaka Natsumi, Sakamoto Tomohiro, Yamaguchi Kosuke, Makino Haruhiko, Igishi Tadashi, Yamasaki Akira. Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature.. Molecular and clinical oncology. 2019. DOI: 10.3892/mco.2019.1923.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.